Health Care

Cronos Group’s Q4 earnings miss reveals forex‑driven earnings pressure, yet revenue beats and strategic moves—including a European acquisition and Cyprus gas project—signal growth potential.

BioMarin’s FDA approval expands PALYNZIQ to 12‑year‑old PKU patients, boosting sales and analyst targets to $104—key for investors watching earnings and growth prospects.

Discover how Anavex Life Sciences Corp is advancing precision genetic medicine for rare neurological disorders, with CEO insights and board expansion fueling innovation.

Moderna’s mCOMBRIAX gets EU approval as the first combined COVID‑flu mRNA shot, promising single‑dose protection and a new revenue stream for the company.

Johnson & Johnson’s latest oncology breakthrough, new CereGlide device launch, and legal challenges are reshaping its $584B health‑care strategy, boosting investor confidence.

Discover how Eli Lilly’s new diabetes‑obesity drug, expanded Olumiant approval, and AI‑powered LillyPod partnership are reshaping its competitive edge and investor appeal.

Ventripoint Diagnostics: a low‑cost, bolt‑on 3‑D cardiac imaging solution that boosts accuracy, drives subscription revenue, and scales without new hardware—transforming hospital diagnostics.

ORIC Pharmaceuticals, a Nasdaq‑listed cancer‑treatment biotech, shows strong growth potential despite negative earnings; investors eye its latest research and upcoming investor conferences for future value.

Omeros Corp. completes primate study for OncotoX‑AML™—a critical step toward targeted AML therapy, boosting investor interest amid volatile biotech markets.

Jaguar Health’s new one‑time stock dividend shows its commitment to shareholders amid a challenging financial climate, highlighting its natural‑pharma focus and future growth prospects.